A. Calling of the Roll

B. Declaration of Conflicts


D. UW-Madison Clinical Trial Agreement with I-Mab Biopharma US Limited

E. UW-Madison Clinical Trial Agreement with IQVIA RDS Inc.

F. UW-Madison Master Research Agreement with Canoo Technologies, Inc.
UW-MADISON CLINICAL TRIAL AGREEMENT
WITH PHARMACEUTICAL RESEARCH ASSOCIATES, INC.

REQUESTED ACTION

Adoption of Resolution C., approving the contractual clinical trial agreement between the Board of Regents and Pharmaceutical Research Associates, Inc.

Resolution C. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual clinical trial agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Pharmaceutical Research Associates, Inc.

SUMMARY


The clinical trial, to be run by the UW Carbone Cancer Center, will study the safety and tolerability of Arvinas' drug ARV-766 in patients with prostate cancer. The trial will also explore how the medicine moves throughout the body and how the drug works. This study will offer another treatment option to patients with resistant metastatic cancer. The potential total budget for this trial is expected to exceed $1.1 million.

Presenter:

- Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison

BACKGROUND

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.
Related Policies

- Regent Policy Document 13-1, “General Contract Approval, Signature Authority, and Reporting”
REQUESTED ACTION

Adoption of Resolution D., approving the contractual clinical trial agreement between the Board of Regents and I-Mab Biopharma US Limited.

Resolution D. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual clinical trial agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and I-Mab Biopharma US Limited.

SUMMARY

The UW-Madison School of Medicine and Public Health seeks approval of an agreement with I-Mab Biopharma US Limited (I-Mab), the Maryland-based office of the global clinical-stage biopharmaceutical company.

The clinical trial, to be run by the UW Carbone Cancer Center, will explore the safety and effectiveness of I-Mab's TJ033721 drug in patients with advanced metastatic solid tumors, whose disease has not responded to any currently FDA-approved treatments. This trial will provide yet another option to patients with advanced cancers. The dollar value of the agreement over the term of the trial is estimated to exceed $2.5 million.

Presenter:

- Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison

BACKGROUND

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.
Related Policies

- Regent Policy Document 13-1, “General Contract Approval, Signature Authority, and Reporting”
UW-MADISON CLINICAL TRIAL AGREEMENT
WITH IQVIA RDS, INC.

REQUESTED ACTION

Adoption of Resolution E., approving the contractual clinical trial agreement between the Board of Regents and IQVIA RDS Inc.

Resolution E. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual clinical trial agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and IQVIA RDS, Inc.

SUMMARY

The UW-Madison School of Medicine and Public Health seeks approval of an agreement with IQVIA RDS Inc. to conduct a clinical trial sponsored by Dragonfly Therapeutics, an American pharmaceutical company founded in 2015 to provide breakthrough cancer treatments for patients. Dragonfly's novel cytokines and "TriNKET" NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.

The clinical trial, to be run by the UW Carbone Cancer Center, will assess the safety and tolerability of the drug DF1001, and determine the Maximum Tolerated Dose (MTD) in patients with advanced solid tumors for whom no effective standard therapy exists, or have recurrent disease, or are intolerant of standard therapies.

This is UW-Madison's first study with Dragonfly Therapeutics. The dollar value of the agreement over the term of the trial is estimated to exceed $1.5 million.

Presenter:

- Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison
BACKGROUND

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.

Related Policies

- Regent Policy Document 13-1, “General Contract Approval, Signature Authority, and Reporting”
REQUESTED ACTION

Adoption of Resolution F., approving the contractual master research agreement between the Board of Regents and Canoo Technologies, Inc.

Resolution F. That, upon recommendation of the Chancellor of the University of Wisconsin-Madison and the President of the University of Wisconsin System, the Board of Regents approves the contractual master research agreement between the Board of Regents of the University of Wisconsin System, doing business as UW-Madison, and Canoo Technologies, Inc.

SUMMARY

Canoo Technologies is an American startup company that manufactures electric vehicles. The company's current focus is on minivan and commercial electric vehicles. This master research agreement between Canoo Technologies and UW-Madison creates a pathway for the parties to quickly collaborate on core research and directed research of interest. If this relationship is successful, Canoo will be looking to build a facility in Madison, likely in University Research Park.

Under this five-year agreement, $600,000 annually will be provided for directed research of interest between UW-Madison’s College of Engineering and Canoo Technologies, and $500,000 annually will be directed toward establishing a core facility within the College of Engineering.

Presenter:

- Rob Cramer, Interim Vice Chancellor for Finance and Administration, UW-Madison
BACKGROUND

Regent Policy Document 13-1 requires any grant or contract with private, profit-making organizations in excess of $1,000,000 be presented to the Board of Regents for formal approval prior to execution.

Related Policies

- Regent Policy Document 13-1, “General Contract Approval, Signature Authority, and Reporting”